公开(公告)号：US20220218850A1

公开(公告)日：2022-07-14

申请号：US17574790

申请日：2022-01-13

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Luni Emdad ,  Praveen Bhoopathi ,  Anjan K. Pradhan ,  Swadesh K. Das ,  Alexander L. Klibanov

IPC: A61K49/22 ,  A61K45/06 ,  A61K31/7115

Abstract: In various aspects, the present disclosure provides methods, compositions, and kits for treating a target tissue with one or more active agents. In embodiments, delivering an active agent to a target tissue comprises administration of microbubbles and ultrasound.

公开(公告)号：US20210147502A1

公开(公告)日：2021-05-20

申请号：US17082523

申请日：2020-10-28

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Praveen Bhoopathi ,  Swadesh K. Das ,  Luni Emdad ,  Devanand Sarkar ,  Upneet Sokhi

IPC: C07K14/54

Abstract: Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

公开(公告)号：US20160101193A1

公开(公告)日：2016-04-14

申请号：US14895247

申请日：2014-06-04

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Rupesh Dash ,  Devanand Sarkar ,  Siddik Sarkar ,  Jolene Windle

IPC: A61K48/00 ,  A61K49/00 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  A61K35/761 ,  A61K49/0008 ,  A61K49/005 ,  C12N15/86 ,  C12N2015/8536 ,  C12N2015/8572 ,  C12N2710/10332 ,  C12N2830/008 ,  C12N2830/34

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

Abstract translation: 提供其中一种或多种元件的表达（例如病毒复制所需的基因，可检测的成像剂，治疗剂等）由截短的CCN 1癌选择性启动子（tCCN1-Prom）驱动的重组载体，细胞和 含有这些载体的转基因动物。 这些载体用于癌症治疗和/或诊断，并且转基因小鼠用于监测癌症进展。 在筛选试验中。

公开(公告)号：US10597728B2

公开(公告)日：2020-03-24

申请号：US15574283

申请日：2016-05-13

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Paul B. Fisher ,  Manny Bacolod

IPC: C12Q1/6886

Abstract: Methods of prognosing the outcome of cancer and/or cancer treatment are provided. The methods involve quantitating the level of methylation at a site that regulates expression of the mda-9/Syntenin gene, site cg17197774. High levels of methylation indicate a good prognosis whereas low levels of methylation indicate a poor prognosis and determination of these levels permits risk stratification of patients with cancer.

公开(公告)号：US10166300B2

公开(公告)日：2019-01-01

申请号：US14895556

申请日：2014-06-04

Applicant: Virginia Commonwealth University ,  The Johns Hopkins University

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Mitchell E. Menezes ,  Devanand Sarkar ,  Martin G. Pomper

IPC: A61K51/00 ,  A61K9/14 ,  C12N15/63 ,  C07H21/04 ,  A61K48/00 ,  A61K41/00 ,  A61K49/00 ,  A61K51/04 ,  C12Q1/6897 ,  A61K9/00 ,  C12N15/86 ,  A61K38/20 ,  C12N7/00 ,  C12N15/87 ,  A61K51/12

Abstract: The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

公开(公告)号：US20240360138A1

公开(公告)日：2024-10-31

申请号：US18537700

申请日：2023-12-12

Applicant: Virginia Commonwealth University ,  Sanford Burnham Prebys Medical Discovery Institute

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

Abstract: Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US11891399B2

公开(公告)日：2024-02-06

申请号：US17148813

申请日：2021-01-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  C07D495/14 ,  A61P35/04 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14 ,  A61K31/519 ,  A61K2300/00

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US11008325B2

公开(公告)日：2021-05-18

申请号：US16349467

申请日：2017-11-14

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  C07D495/14 ,  A61P35/04 ,  A61K31/519 ,  A61K45/06

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US09750823B2

公开(公告)日：2017-09-05

申请号：US14895247

申请日：2014-06-04

Applicant: Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Rupesh Dash ,  Devanand Sarkar ,  Siddik Sarkar ,  Jolene Windle

IPC: A61K48/00 ,  A61K47/00 ,  A61K49/00 ,  C12N15/00 ,  C12N5/00 ,  A01K67/027 ,  A61K35/761 ,  C12N15/86 ,  C12N15/85

CPC classification number: A61K48/0058 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0393 ,  A61K35/761 ,  A61K49/0008 ,  A61K49/005 ,  C12N15/86 ,  C12N2015/8536 ,  C12N2015/8572 ,  C12N2710/10332 ,  C12N2830/008 ,  C12N2830/34

Abstract: Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

公开(公告)号：US09994865B2

公开(公告)日：2018-06-12

申请号：US14895125

申请日：2014-06-04

Applicant: The Johns Hopkins University ,  Virginia Commonwealth University

Inventor： Paul B. Fisher ,  Swadesh K. Das ,  Mitchell E. Menezes ,  Devanand Sarkar ,  Martin G. Pomper

IPC: A61K48/00 ,  C12N15/85 ,  C12N15/64 ,  C07K14/47 ,  G01N33/50 ,  G01N33/574 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K41/00 ,  A61K49/00 ,  A61N7/00 ,  C07K14/36 ,  C07K14/465 ,  C07K14/54 ,  C12N7/00 ,  C12N15/86 ,  C12N15/62 ,  B82Y5/00 ,  B82Y15/00

CPC classification number: C12N15/85 ,  A61K38/164 ,  A61K38/1703 ,  A61K38/20 ,  A61K41/0028 ,  A61K48/00 ,  A61K48/0058 ,  A61K48/0075 ,  A61K49/00 ,  A61N7/00 ,  A61N2007/0039 ,  B82Y5/00 ,  B82Y15/00 ,  C07K14/36 ,  C07K14/465 ,  C07K14/47 ,  C07K14/54 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C12N7/00 ,  C12N15/625 ,  C12N15/64 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2799/02 ,  C12N2799/022 ,  C12N2800/22 ,  C12N2810/855 ,  C12N2830/002 ,  C12N2830/008 ,  G01N33/50 ,  G01N33/574

Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.